NorthCrest Asset Manangement’s ADMA Biologics ADMA Stock Holding History

NorthCrest Asset Manangement’s Portfolio ADMA Stock Details ADMA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$136K	Sell	14,718 -5,615	-28%	-$51.2K	﹤0.01%	887
2026 Q1	$187K	Buy	20,333 +437	+2%	+$6.9K	0.01%	733
2025 Q4	$359K	Hold	19,896	–	–	0.01%	635
2025 Q3	$278K	Buy	19,896 +6,109	+44%	+$105K	0.01%	643
2025 Q2	$252K	Sell	13,787 -7,900	-36%	-$161K	0.01%	563
2025 Q1	$430K	Buy	+21,687	New	+$375K	0.01%	449

Other funds holding ADMA

AAP

Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

YCM

Yousif Capital Management Bloomfield Hills, Michigan $8.94B AUM 42.6% 1-Year Est. Return

COPPSERS

Commonwealth of Pennsylvania Public School Employees Retirement System Harrisburg, Pennsylvania $20.6B AUM 37.37% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

FCBT

First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return

EWM

Empirical Wealth Management Seattle, Washington $6.85B AUM 30.02% 1-Year Est. Return

KPP

Kings Path Partners Sugar Land, Texas $376M AUM 19% 1-Year Est. Return

CWP

Curated Wealth Partners El Segundo, California $774M AUM 5.71% 1-Year Est. Return

NorthCrest Asset Manangement's ADMA Position: Q2 2026 in Review

NorthCrest Asset Manangement reduced its ADMA Biologics (ADMA) stake by 28% in Q2 2026, selling an estimated $51.2K and leaving 14,718 shares worth $136K. The position accounts for ﹤0.01% of the portfolio, ranked #887.

NorthCrest Asset Manangement first reported a position in ADMA in Q1 2025 and has held it in 6 quarters since. The position peaked at $430K in Q1 2025. 27 funds tracked by Wall St. Rank hold ADMA as of Q2 2026.

NorthCrest Asset Manangement held 14,718 shares of ADMA Biologics worth $136K as of Q2 2026.
NorthCrest Asset Manangement sold 5,615 ADMA Biologics shares in Q2 2026, an estimated $51.2K.
ADMA Biologics made up ﹤0.01% of NorthCrest Asset Manangement's portfolio in Q2 2026, its #887 holding.
NorthCrest Asset Manangement first reported a position in ADMA Biologics in Q1 2025 and has held it in 6 quarters since.
NorthCrest Asset Manangement's ADMA Biologics position peaked at $430K in Q1 2025.
27 funds tracked by Wall St. Rank held ADMA Biologics as of Q2 2026.

Based on NorthCrest Asset Manangement's 13F filing for Q2 2026, filed 15 Jul 2026.